Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

[1]  Jason P. Mendoza,et al.  Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis , 2022, Neurology and Therapy.

[2]  E. Swallow,et al.  Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison. , 2022, Multiple sclerosis and related disorders.

[3]  M. Konwar,et al.  Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis. , 2022, Multiple sclerosis and related disorders.

[4]  D. Arnold,et al.  Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study , 2022, Advances in Therapy.

[5]  M. Inglese,et al.  Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis , 2021, Neurotherapeutics.

[6]  S. Cohan,et al.  Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison , 2021, CNS Drugs.

[7]  C. Pozzilli,et al.  Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study , 2021, JAMA neurology.

[8]  C. Louapre,et al.  Comparative effectiveness of dimethyl fumarate in multiple sclerosis , 2021, British journal of clinical pharmacology.

[9]  R. Gold,et al.  Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study , 2021, Therapeutic advances in neurological disorders.

[10]  MSVirtual 2020 – Poster Abstracts , 2020 .

[11]  G. Harty,et al.  Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options , 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

[12]  M. Freedman,et al.  Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study , 2020, CNS Drugs.

[13]  R. Iodice,et al.  Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. , 2019, Multiple sclerosis and related disorders.

[14]  D. Arnold,et al.  Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study , 2019, Multiple sclerosis.

[15]  P. Vermersch,et al.  Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis , 2019, Neurology.

[16]  Yanli Zhang,et al.  Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis , 2019, Journal of Neurology.

[17]  Devon S. Conway,et al.  Prognostic factors of disability in relapsing remitting multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[18]  P. Sørensen,et al.  Comparative effectiveness of teriflunomide and dimethyl fumarate , 2019, Neurology.

[19]  B. Pereira,et al.  Dimethyl fumarate and teriflunomide for multiple sclerosis in a real‐life setting: a French retrospective cohort study , 2018, European journal of neurology.

[20]  F. Pellegrini,et al.  Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry , 2018, Journal of Neurology.

[21]  M. Sormani,et al.  Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas , 2018, Annals of neurology.

[22]  F. Fernandez‐Llimos,et al.  Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis , 2018, CNS Drugs.

[23]  M. Greenwood,et al.  Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments , 2017, Front. Neurol..

[24]  Sofia Dias,et al.  Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[25]  Jeffrey A. Cohen,et al.  Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up , 2017, Multiple sclerosis journal - experimental, translational and clinical.

[26]  G. Cutter,et al.  Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. , 2017, Journal of comparative effectiveness research.

[27]  R. Fox,et al.  Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis , 2017, Current medical research and opinion.

[28]  Irina Proskorovsky,et al.  Simulation and Matching-Based Approaches for Indirect Comparison of Treatments , 2015, PharmacoEconomics.

[29]  T. Schenk,et al.  Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis , 2014, Therapeutic advances in neurological disorders.

[30]  Mei Lu,et al.  Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  George C. Ebers,et al.  The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability , 2010, Brain : a journal of neurology.

[32]  K. Rothman.  Epidemiology: An Introduction , 2002 .

[33]  Eric Q. Wu,et al.  Comparative Effectiveness Without Head-to-Head Trials , 2012, PharmacoEconomics.